← FDA DRUG APPROVALS

FDA ANDA · ANDA065285

DOXYCYCLINE

Sponsor: LANNETT CO INC

APPLICATION
ANDA065285
TYPE
ANDA
ORIGINAL APPROVAL
2005-12-08
LATEST ACTION
2015-05-08
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

DOXYCYCLINEPrescription
DOXYCYCLINE EQ 75MG BASE · TABLET · ORAL
DOXYCYCLINEPrescription
DOXYCYCLINE EQ 50MG BASE · TABLET · ORAL
DOXYCYCLINEPrescription
DOXYCYCLINE EQ 150MG BASE · TABLET · ORAL
DOXYCYCLINEPrescription
DOXYCYCLINE EQ 100MG BASE · TABLET · ORAL

Approval history

2015-05-08Manufacturing (CMC) · Supplement 18 · unknownAP
2014-12-02Labeling · Supplement 19 · standardAP
2008-07-30Labeling · Supplement 9AP
2008-07-30Labeling · Supplement 5AP
2005-12-08OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →